Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
Legend Biotech Corp. (LEGN) PT Raised to $83 at Cantor Fitzgerald
November 13, 2024 7:21 AM ESTCantor Fitzgerald analyst Rick Bienkowski raised the price target on Legend Biotech Corp. (NASDAQ: LEGN) to $83.00 (from $82.00) while maintaining a Overweight rating.
The analyst comments "The debate over anito-cel's (ACLX, OW) ASH abstract data overshadowed much of the 3Q24 LEGN earnings call, with management vigorously arguing in favor of Carvykti's efficacy and safety profile. We published on anito-cel's abstract... More
